AlloVir - ALVR Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALVR shares.
View ALVR analyst ratings or view top-rated stocks.

3 equities research analysts have issued twelve-month price targets for AlloVir's shares. Their ALVR share price forecasts range from $19.00 to $34.00. On average, they expect the company's stock price to reach $24.33 in the next year. This suggests a possible upside of 499.3% from the stock's current price.
View analysts price targets for ALVR or view top-rated stocks among Wall Street analysts.

AlloVir's stock was trading at $5.13 at the beginning of the year. Since then, ALVR shares have decreased by 20.9% and is now trading at $4.06.
View the best growth stocks for 2023 here.

AlloVir saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 5,420,000 shares, an increase of 20.4% from the February 13th total of 4,500,000 shares. Based on an average daily volume of 257,100 shares, the days-to-cover ratio is currently 21.1 days.
View AlloVir's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ALVR earnings forecast.

AlloVir, Inc. (NASDAQ:ALVR) posted its earnings results on Thursday, August, 5th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.14.

ETFs with the largest weight of AlloVir (NASDAQ:ALVR) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), ProShares Ultra Nasdaq Biotechnology (BIB) and Invesco Nasdaq Biotechnology ETF (IBBQ),

Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL).

(ALVR) raised $252 million in an IPO on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

AlloVir trades on the NASDAQ under the ticker symbol "ALVR."

AlloVir's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alkeon Capital Management LLC (4.94%), JPMorgan Chase & Co. (1.03%), Geode Capital Management LLC (0.82%), Renaissance Technologies LLC (0.44%), Charles Schwab Investment Management Inc. (0.33%) and Morgan Stanley (0.24%). Insiders that own company stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Beek Jeroen B Van, Brett R Hagen, David Hallal, Diana Brainard, Edward Miller, Ercem Atillasoy, Jeffrey S Bornstein, John Robert Wilson, Juan Vera, Morana Jovan-Embiricos and Vikas Sinha.
View institutional ownership trends.

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALVR stock can currently be purchased for approximately $4.06.

AlloVir (NASDAQ:ALVR) has a market capitalization of $379.45 million. The company earns $-168,710,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis.

The company employs 107 workers across the globe.

AlloVir's mailing address is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. The official website for the company is www.allovir.com. The company can be reached via phone at 617-433-2605 or via email at ir@allovir.com.